Press releases

Pharnext participates in the 2023 CMTA Patient & Research Summit


PARIS, France, November 3, 2023, 09:30 am CET – Pharnext SA (FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its participation in the 2023 CMTA Patient & Research Summit, a hybrid experience which includes an in-person event on Saturday, November 4th in Boston, Massachusetts, and the opportunity to attend virtually.

The 2023 CMTA Patient & Research Summit will offer life-improving presentations on living well with Charcot-Marie-Tooth disease (CMT), learning how to manage CMT symptoms and hear what do to be involved in advancing research through clinical trials and studies.

Pharnext is pleased to participate in this patient-focused event and strengthen its ties with the CMT community as its lead candidate, PXT3003, is currently completing its pivotal Phase III clinical development for treatment of the most common subtype 1A (CMT1A), with results read-out planned for December 2023.

Dr Gilbert Wagener, Chief Medical Officer of Pharnext, will be part of the STAR Breakout CMT type 1 Session, on November 4th at 1:35 - 2:45 pm Eastern Time.
He will provide an overview of PXT3003’s clinical development and regulatory progress, update on the pivotal clinical trial being completed and two open-label extension Phase III studies still ongoing with more than 430 CMT1A patients treated with PXT3003. Dr Wagener will comment as well as on the New Drug Application (‘NDA’) submission to prepare for marketing PXT3003, conditional on a positive pivotal Phase III clinical trial and the approval of regulatory agencies.

More information on the 2023 CMTA Patient & Research Summit on November 4th in Boston, and recording, available on their website:

Pharnext arranged convertible bonds financing (OCEAN-BSA) with Global Tech Opportunities 13 which, after receiving the shares resulting from the conversion or exercise of these instruments, will not remain shareholder of the Company.
The shares resulting from the conversion or exercise of the above-mentioned securities will generally be sold on the market at very short notice, which may create strong downward pressure on the share price.
Shareholders may suffer a loss of their invested capital due to a significant fall in the Company's share price, as well as significant dilution due to the large number of securities issued to Global Tech Opportunities 13.
Investors are advised to exercise extreme caution before deciding to invest in the securities of a listed company that carries out such dilutive financing transactions, particularly when they are carried out in succession. The Company wishes to point out that this is not the first dilutive financing transaction it has undertaken.
Investors are invited to familiarize themselves with the risks associated with these transactions, as mentioned in the press release above.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases currently without satisfactory therapeutic solutions. Pharnext has a first-in-class drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating, inherited peripheral neuropathy. PXT3003 benefits from orphan drug status in Europe and the United States. In 2018, PXT3003 completed a Phase III clinical trial, the PLEO-CMT trial, with encouraging topline results. This trial was followed by an open-label extension study, the PLEO-CMT-FU trial, with 120 patients continuing treatment with PXT3003. Long-term data suggest a sustained benefit, safety, and efficacy, after 6 years of total trial time. An international pivotal Phase III study of PXT3003, the PREMIER trial, enrolling 387 CMT1A patients was completed in August 2023. PREMIER topline results are expected in Q4 2023. PXT3003 originated from the Pleotherapy™ R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR001400JXB0).